Oxytocin and vasopressin systems in obesity and metabolic health: Mechanisms and perspectives

Research output: Contribution to journal › Review › Research › peer-review

Standard

Oxytocin and vasopressin systems in obesity and metabolic health : Mechanisms and perspectives. / Ding, Cherlyn; Magkos, Faidon.

In: Current Obesity Reports, Vol. 8, No. 3, 2019, p. 301-316.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Ding, C & Magkos, F 2019, 'Oxytocin and vasopressin systems in obesity and metabolic health: Mechanisms and perspectives', Current Obesity Reports, vol. 8, no. 3, pp. 301-316. https://doi.org/10.1007/s13679-019-00355-z

APA

Ding, C., & Magkos, F. (2019). Oxytocin and vasopressin systems in obesity and metabolic health: Mechanisms and perspectives. Current Obesity Reports, 8(3), 301-316. https://doi.org/10.1007/s13679-019-00355-z

Vancouver

Ding C, Magkos F. Oxytocin and vasopressin systems in obesity and metabolic health: Mechanisms and perspectives. Current Obesity Reports. 2019;8(3):301-316. https://doi.org/10.1007/s13679-019-00355-z

Author

Ding, Cherlyn ; Magkos, Faidon. / Oxytocin and vasopressin systems in obesity and metabolic health : Mechanisms and perspectives. In: Current Obesity Reports. 2019 ; Vol. 8, No. 3. pp. 301-316.

Bibtex

@article{d34e2a63705b4d22a9dc1b254e6c21d5,
title = "Oxytocin and vasopressin systems in obesity and metabolic health: Mechanisms and perspectives",
abstract = "Purpose of review: The neurohypophysial endocrine system is identified here as a potential target for therapeutic interventions toward improving obesity-related metabolic dysfunction, given its coinciding pleiotropic effects on psychological, neurological and metabolic systems that are disrupted in obesity.Recent findings: Copeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes. Plasma oxytocin is decreased in obesity and several other conditions of abnormal glucose homeostasis. Recent data also show non-classical tissues, such as myocytes, hepatocytes and β-cells, exhibit responses to oxytocin and vasopressin receptor binding that may contribute to alterations in metabolic function. Summary: The modulation of anorexigenic and orexigenic pathways appears to be the dominant mechanism underlying the effects of oxytocin and vasopressin on body weight regulation; however, there are apparent limitations associated with their use in direct pharmacological applications. A clearer picture of their wider physiological effects is needed before either system can be considered for therapeutic use.",
keywords = "Faculty of Science, Insulin resistance, Beta-cell function, Energy exoenditure, Neurohypophysis, Substrate metabolism, Vasopressin",
author = "Cherlyn Ding and Faidon Magkos",
note = "CURIS 2019 NEXS 252",
year = "2019",
doi = "10.1007/s13679-019-00355-z",
language = "English",
volume = "8",
pages = "301--316",
journal = "Current Obesity Reports",
issn = "2162-4968",
publisher = "Springer Healthcare",
number = "3",

}

RIS

TY - JOUR

T1 - Oxytocin and vasopressin systems in obesity and metabolic health

T2 - Mechanisms and perspectives

AU - Ding, Cherlyn

AU - Magkos, Faidon

N1 - CURIS 2019 NEXS 252

PY - 2019

Y1 - 2019

N2 - Purpose of review: The neurohypophysial endocrine system is identified here as a potential target for therapeutic interventions toward improving obesity-related metabolic dysfunction, given its coinciding pleiotropic effects on psychological, neurological and metabolic systems that are disrupted in obesity.Recent findings: Copeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes. Plasma oxytocin is decreased in obesity and several other conditions of abnormal glucose homeostasis. Recent data also show non-classical tissues, such as myocytes, hepatocytes and β-cells, exhibit responses to oxytocin and vasopressin receptor binding that may contribute to alterations in metabolic function. Summary: The modulation of anorexigenic and orexigenic pathways appears to be the dominant mechanism underlying the effects of oxytocin and vasopressin on body weight regulation; however, there are apparent limitations associated with their use in direct pharmacological applications. A clearer picture of their wider physiological effects is needed before either system can be considered for therapeutic use.

AB - Purpose of review: The neurohypophysial endocrine system is identified here as a potential target for therapeutic interventions toward improving obesity-related metabolic dysfunction, given its coinciding pleiotropic effects on psychological, neurological and metabolic systems that are disrupted in obesity.Recent findings: Copeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes. Plasma oxytocin is decreased in obesity and several other conditions of abnormal glucose homeostasis. Recent data also show non-classical tissues, such as myocytes, hepatocytes and β-cells, exhibit responses to oxytocin and vasopressin receptor binding that may contribute to alterations in metabolic function. Summary: The modulation of anorexigenic and orexigenic pathways appears to be the dominant mechanism underlying the effects of oxytocin and vasopressin on body weight regulation; however, there are apparent limitations associated with their use in direct pharmacological applications. A clearer picture of their wider physiological effects is needed before either system can be considered for therapeutic use.

KW - Faculty of Science

KW - Insulin resistance

KW - Beta-cell function

KW - Energy exoenditure

KW - Neurohypophysis

KW - Substrate metabolism

KW - Vasopressin

U2 - 10.1007/s13679-019-00355-z

DO - 10.1007/s13679-019-00355-z

M3 - Review

C2 - 31240613

VL - 8

SP - 301

EP - 316

JO - Current Obesity Reports

JF - Current Obesity Reports

SN - 2162-4968

IS - 3

ER -

ID: 225375987